What Quantum Genomics does

Quantum Genomics is a publicly listed French biopharmaceutical company founded in 2006 and headquartered in Paris, focused on developing therapies for unmet medical needs in the field of cardiovascular diseases. The company trades on Euronext Paris under the ticker ALQGC and operates with a small specialized workforce of 11-50 employees, indicating a clinical-stage or early-commercial organizational footprint typical of European small-cap biotech. Corporate leadership is anchored by Chief Executive Officer and Managing Director Jean-Philippe Milon, with Benoît Gueugnon serving as Administrative and Financial Director.

The company's business model centers on proprietary drug development targeting cardiovascular indications, a therapeutic area with significant unmet medical need and large addressable markets. No specific product candidates, pipeline assets, clinical trial milestones, or technological platforms are disclosed in the available input data, limiting visibility into the precise mechanism of value creation. The firm has executed at least one inorganic growth action — the 2007 acquisition of Eurobiobiz for an undisclosed amount — establishing a precedent for M&A-driven capability expansion, though no subsequent transactions are documented.

Capital structure reflects reliance on public equity markets for funding ongoing R&D, consistent with the long development timelines typical of cardiovascular therapeutics. The available financial disclosures are internally inconsistent and contain figures (e.g., revenues in the billions and losses in the trillions) that are not credible for a company of this size and profile, which materially impairs revenue and growth assessment. No named customers, commercial partners, distribution agreements, or end-market segmentation data are disclosed, leaving commercialization strategy and revenue concentration effectively undocumented in the current evidence base.

Name

Quantum Genomics

Website

https://quantum-genomics.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Quantum Genomics is a publicly listed, Paris-based biopharmaceutical company founded in 2006 that develops therapies for unmet medical needs in cardiovascular diseases, operating with a small specialized team of 11-50 employees under Euronext Paris ticker ALQGC.

Ownership category

akta.pro rank

Product category

Cardiovascular Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)

Keywords

• Cardiovascular therapeutics
• Hypertension drug development
• Biopharmaceutical research
• Heart failure treatments
• Clinical stage biotechnology

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Affiliate Commissions: NouveauCasino acts as an affiliate, earning commissions when users click affiliate links and complete qualifying actions (registration, deposit) at partnered online casino operators. Commercial agreements are strictly separated from editorial ranking decisions.
2. Advertising Revenue: The site generates revenue through advertising partnerships with online casino operators, clearly identified as affiliate links.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Quantum Genomics develops therapies for unmet medical needs in the field of cardiovascular diseases. The company focuses on biopharmaceutical research and development of novel drug compounds targeting hypertension and related cardiovascular conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Cardiovascular disease therapies (pipeline) Therapeutic drug candidates developed for unmet medical needs in cardiovascular disease, targeting hypertension and related cardiovascular conditions. Offered to patients via healthcare providers and through potential pharmaceutical partnerships.

Quantifiable outcome

• Complete casino testing methodology covering registration, deposits, withdrawals, and customer service evaluation
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• BetcliccoreChannel Partner/ Reseller/ DistributorLeading ANJ-licensed online casino operator in France. NouveauCasino provides affiliate traffic and player referrals in exchange for commission on qualified registrations and deposits. Featured extensively in bonus comparisons and casino reviews.
• UnibetcoreChannel Partner/ Reseller/ DistributorANJ-licensed operator offering casino games, poker, and sports betting. NouveauCasino features Unibet in welcome bonus comparisons, payment method guides, and game variety reviews. Affiliate relationship drives player acquisition.
• WinamaxcoreChannel Partner/ Reseller/ DistributorANJ-licensed online poker and casino platform popular in France. Featured in bonus guides, KYC testing, and responsible gambling tool comparisons. Affiliate traffic generates commission for NouveauCasino.
• BwinminorChannel Partner/ Reseller/ DistributorANJ-licensed casino and sports betting operator. Mentioned in bonus comparisons and payment method guides as a partnered operator receiving affiliate referrals.
• FDJ (Française des Jeux)minorChannel Partner/ Reseller/ DistributorState-owned lottery and gaming operator with ANJ license. Referenced for responsible gambling features like 'Pause 24h' option and lottery/gaming offerings.

Scale indicators4 records

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Novartis: Global pharmaceutical leader with one of the largest cardiovascular franchises (Entresto, etc.). Represents the broad incumbent competitive backdrop against which a small cardiovascular specialist like Quantum Genomics must position.
• AstraZeneca: Global pharma with a substantial cardiovascular, renal, and metabolism franchise (Farxiga, Brilinta). Represents a key incumbent competitor and a credible acquirer of differentiated cardiovascular assets that Quantum Genomics might seek to develop or partner.
• Servier: Large French private pharmaceutical company with a long-standing cardiovascular franchise. Servier provides a domestic French peer benchmark and represents both a competitor and a potential partner/acquirer for a French-listed cardiovascular specialist like Quantum Genomics.
• Bayer: Major pharmaceutical company with an established cardiovascular portfolio (Xarelto/Eliquis franchises). Bayer represents both a competitive threat and a potential strategic acquirer for focused cardiovascular specialists like Quantum Genomics.

Regional players

• Valneva: French-listed specialty biotech focused on vaccines and infectious diseases. Comparable to Quantum Genomics as a fellow French-listed small-cap biotech with similar capital-markets dynamics and European biotech operating profile.
• Innate Pharma: French-listed clinical-stage biotech developing immuno-oncology therapies. Comparable to Quantum Genomics as a French small-cap listed biotech serving as a relevant benchmark for European biotech capital-raising dynamics.
• Genfit: French-listed clinical-stage biotech headquartered in France. As a fellow small-cap French biotech, Genfit provides a comparable benchmark for capital-markets dynamics, investor base, and European listing economics relevant to Quantum Genomics.
• Abivax: French-listed clinical-stage biotech developing inflammatory disease therapies. Comparable to Quantum Genomics in size, listed status on Euronext, and small-team European biotech operating model, even though the therapeutic area differs.

Direct peers

• Idorsia Pharmaceuticals: Swiss-listed specialty pharma focused on cardiovascular and central nervous system therapies with a small, R&D-heavy organization comparable to Quantum Genomics. Both companies target specialty indications with high unmet need and rely on capital markets to fund late-stage development.

Emerging players

• Mineralys Therapeutics: US clinical-stage biotech developing therapies for resistant and uncontrolled hypertension — a directly comparable cardiovascular indication to Quantum Genomics' focus. Both companies target high-unmet-need cardiovascular subsegments with novel mechanisms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/quantumgenomics
• LinkedInlinkedin.com/company/5186305

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantum Genomics